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© 2012 The Japan Society of Histochemistry and Many malignant epithelial tumors show increased expression of glucose transporter-1 (GLUT-
1) and hexokinase II (HK-II), both of which are involved in glucose metabolism. GLUT-1
levels are often correlated with prognosis in these tumors. The current retrospective study
was conducted to evaluate the importance of GLUT-1 and HK-II expression in leiomyosarcoma
(LMS), a malignant uterine non-epithelial tumor with a poor prognosis. The subjects were
23 patients with stage I LMS. Expression of GLUT-1 and HK-II was evaluated immuno-
histochemically in samples removed surgically, and the MIB-1 index was evaluated as a
measure of cell proliferation. The association of these results with prognosis was examined.
Twenty samples of leiomyoma (LOM), a benign non-epithelial tumor, were used as controls.
Immunohistochemical expression was defined as negative staining (–), weak to sporadic
staining (1+), and strong staining (2+) per microscopic field, respectively. Malignancy was
evaluated in 2000 cells and the MIB-1 index was calculated. Overall survival for LMS was
estimated using the Kaplan-Meier method. Of the LMS cases, 12 were GLUT-1-positive
(52.2%; 2+: 2, 1+: 10) and 15 were HK-II-positive (65.2%; 2+: 1, 1+: 14). GLUT-1 expression
in LMS was significantly correlated with the MIB1 index. The 10-year survival rates were
90.9% and 58.3% in GLUT-1-negative and GLUT-1-positive cases, respectively, and 75.0%
and 73.3% in HK-II-positive and HK-II-negative cases, respectively. GLUT-1 expression was
significantly correlated with prognosis. Cases of stage I LMS showed a significant correlation
between the expression level of GLUT-1 and the MIB-1 index, an indicator of malignancy.
GLUT-1-negative cases had a better prognosis than GLUT-1-positive cases, suggesting that
GLUT-1 expression is an effective prognostic marker.
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I. Introduction
Leiomyosarcoma (LMS) is a malignant uterine non-
epithelial tumor that accounts for 1% to 3% of all malignant
tumors in women. LMS has a poor prognosis, since the
primary tumor is likely to undergo recurrence and metastasis
[7]. Tissue necrosis and higher mitotic rates are important
indicators for malignancy and prognosis [18, 29, 40]. More
than 80% of cases of stage III LMS show recurrence and
metastasis and the 5-year survival rate in cases of stages
II–IV is approximately 8%, indicating an extremely poor
prognosis [9, 33]. Surgery is the first option for LMS
treatment; however, even if LMS is in the early stage andTsukada et al. 148
can be completely removed, distant metastasis to the lung
often occurs and results in a poor long-term prognosis
[22]. Radiotherapy and combination chemotherapy with
doxorubicin have also been used for LMS, but treatment
outcomes remain poor [22, 34].
Many malignant epithelial tumors show increased
glucose uptake [42]. Expression of glucose transporter-1
(GLUT-1) is often increased in malignant hypoxic cells and
hexokinase II (HK-II) expression also increases. This causes
resistance to radiotherapy and chemotherapy and enhanced
recurrence and metastasis, which underlie the close relation-
ship of GLUT-1 expression with prognosis [2, 10, 15, 28,
37]. In a clinicopathologic study of epithelial ovarian cancer,
we found increased GLUT-1 expression and strong expres-
sion of hypoxia inducible factor-1 (HIF-1α), with a clear
increase in glucose uptake. Similarly, high expression levels
of HIF-1α and GLUT-1 have been shown in clear cell
carcinoma, which also has a poor prognosis and is common
in Japanese patients [16, 43]. Thus, the current study was
performed to examine expression of GLUT-1 and HK-II
and the relationship of these data with the long term
prognosis of LMS, which has not been examined in previous
studies.
II. Materials and Methods
Patients and treatments
The subjects were 23 patients (mean age: 51.5 years
old; range: 35–70 years old) with clinical stage I LMS who
underwent hysterectomy between March 1987 and May
2005 in our hospital. Adjuvant chemotherapy were per-
formed in 14 patients (61%) (CYVADIC, n=12, 86%;
cyclophosphamide 500 mg/m2 and doxorubicin 50 mg/m2
on day 1, vincristine sulfate 1.5 mg/m2 on days 1 and 5, and
dacarbazine 250 mg/m2 on days 1 through 5 for three to
five monthly cycles); IAP, n=1, 7%; doxorubicin 50 mg/m2
and cisplatin 50 mg/m2 on day 1 and ifosfamide 1000
mg/m2 on days 1 through 5 for three monthly cycles; and
weekly TC, n=1, 7%; paclitaxel 60 mg/m2 and carboplatin
AUC 1.7 on day 1 for 16 weekly cycles). The benign con-
trols were 20 specimens of uterine leiomyomas that were
removed surgically in the same period. At least 2 sections
were isolated from each tumor and a tumor with at least
one stained section was judged to be positive. The study
was approved by the institutional review board and informed
consent was obtained from all patients.
Immunohistochemistry and histological examination
Formalin-fixed and paraffin-embedded tissue blocks
were cut into 4-μm sections for immunohistochemistry and
hematoxylin and eosin staining.
The presence of a malignant mesenchymal tumors
was examined based on positive staining for SMA (Sigma
1A4, Sigma Chemical Co., St. Louis, MO), vimentin (clone
V9, DakoCytomation, Glostrup, Denmark), desmin (clone
D33, DakoCytomation, Glostrup, Denmark) and MIB-1
(Ki-67/clonal MIB1, DakoCytomation, Glostrup, Denmark),
and negative staining for CD34 (QBEnd/10, Novocastra,
Newcastle, UK) in an initial histological examination.
GLUT-1 expression was evaluated immunohistochem-
ically using rabbit polyclonal anti-human GLUT-1 antibody
(DAKO, Carpinteria, CA, USA) at a dilution of 1:50. HK-
II expression was evaluated with a polyclonal rabbit anti-
HK-II antibody (Chemicon International, Inc., Temecula,
CA) diluted at 1:500. The sections were washed and then
incubated with anti-rabbit IgG conjugated to horseradish
peroxidase-labeled-dextran polymer (EnVision Kit, DAKO)
for 60 min at room temperature. The extent of GLUT-1 and
HK-II expression was assessed semi-quantitatively accord-
ing to the following scoring scheme: negative staining (–),
weak to sporadic staining (1+), and strong staining (2+). In
judging the staining level, erythrocytes and pancreatic tissue
were used as positive controls for GLUT-1 and HK-II,
respectively.
The histological grade of LMS was evaluated by two
expert pathologists by counting of 2000 cells, with >20
mitosis events in 10 microscopic fields judged to be positive.
These data were used to calculate the MIB-1 index for cell
proliferation.
Statistical analysis
The relationship between immunohistochemical scores
and MIB-1 index was determined by linear regression for
the GLUT-1 and HK-II data. Survival curves related to
immunoreactivity were constructed using the Kaplan-Meier
method and assessed by log-rank test. P<0.05 was considered
to indicate significance in all analyses.
III. Results
Hematoxylin & eosin and immunohistochemical staining
Malignant mesenchymal tumors identified from posi-
tive staining for SMA, vimentin, desmin and MIB-1 and
negative staining for CD34 were excluded from the study
(Fig. 1).
GLUT-1 and HKII expression, and MIB-1 index
Of the 23 cases of stage I LMS, 12 (52.2%) were
GLUT-1-positive, including 2 2+ and 10 1+ cases; and 15
(65.2%) were HK-II-positive, including 1 2+ and 14 1+
cases (Table 1, Figs. 2, 3). The MIB-1 index was ≥5% in
10 cases and <5% in 13 (Fig. 4). Of the 20 benign controls,
2 (10%) were GLUT-1-positive, 4 (20%) were HK-II-
positive, and all showed 1+ staining. MIB-1 was negative
in all control specimens (Table 2).
Relationships of GLUT-1 and HK-II expression with the 
MIB-1 index
GLUT-1 expression levels showed a significant corre-
lation with the MIB-1 index (R2=0.403, p=0.0011, Fig. 4).
In contrast, there was no correlation between HK-II
expression and the MIB-1 index (p=0.703, Fig. 5).Long Term Prognosis Expression Glucose Transporter-1 and Hexokinase II Stage I Uterine Leiomyosarcoma 149
Survival curves based on GLUT-1 expression and HK-II 
expression
The Kaplan-Meier estimates of overall survival (OS)
at 10 years for LMS were 90.9% in the GLUT-1-negative
group and 58.3% in the GLUT-1-positive group, showing
a significant difference in prognosis (Fig. 6). The Kaplan-
Meier estimates of OS at 10 years were 75.0% and 73.3%
in the HK-II-negative and HK-II-positive groups, with no
significant difference between these groups (Fig. 7).
Fig. 1. Malignant mesenchymal tumors detected with hematoxylin-eosin (HE) staining, positive immunostaining for SMA, vimentin, desmin
and MIB-1, and negative immunostaining for CD34. Bar=100 µm.
Fig. 2. Immunohistochemical staining showed strong GLUT-1
expression in sarcoma cell membranes. Bar=100 µm.
Fig. 3. Immunohistochemical staining was strongly positive for
hexokinase (HK)-II in sarcoma cells. Bar=100 µm.Tsukada et al. 150
IV. Discussion
Uterine LMS is likely to show recurrence and metas-
tasis, even in the early stage, and effective treatment has
not been established. In 1985, Omura et al. evaluated 48
cases of stage I and II uterine LMS in a randomized
comparative study, and found recurrence rates of 44% in
Table 1. Characteristics of patients with stage I uterine leiomyosarcoma
Myomec, myomectomy; ATH, abdominal total hysterectomy; BSO, bilateral salpingo-oophorectomy; RSO, right salpingo-oophorectomy; PLN,
pelvic lymph adenectomy; OMT, omentectomy; N, no treatment; CYVADIC, cyclophosphamide, vincristine, doxorubicin and dacarbazine; TC,
paclitaxel and carboplatin.
Case Age Operation Chemotherapy
Expression MIB-1 
Index
Tumor size 
maximum 
(cm) GLUT-1 HK II
1. 48 ATH+RSO N (–) (–) 0.2 3
2. 36 Myomec → ATH+BSO CYVADIC (–) (1+) 0.4 5
3. 38 Myomec → ATH+BSO+PLN CYVADIC (–) (1+) 0.8 10
4. 59 ATH+BSO CYVADIC (–) (1+) 1.1 5
5. 35 ATH+BSO N (–) (1+) 0.1 5
6. 62 ATH+BSO CYVADIC (–) (–) 2.7 6
7. 52 ATH+BSO CYVADIC (–) (–) 3.3 10
8. 42 ATH N (–) (1+) 2.8 6
9. 52 ATH+BSO N (–) (–) 1.6 13
10. 61 ATH+BSO N (1+) (1+) 0.3 8
11. 57 ATH+BSO+PLN CYVADIC (1+) (–) 5.2 11
12. 64 ATH+BSO+PLN N (1+) (–) 37.8 7
13. 58 ATH+BSO CYVADIC (2+) (1+) 23.7 8
14. 70 ATH+BSO N (1+) (1+) 1.9 8
15. 44 ATH+BSO CYVADIC (2+) (1+) 20.0 6
16. 66 ATH+BSO IAP (1+) (1+) 15.0 12
17. 48 ATH+BSO CYVADIC (1+) (1+) 31.9 7
18. 56 ATH+BSO+PLN+OMT Weekly TC (1+) (2+) 3.1 4
19. 45 ATH+BSO N (–) (–) 0.4 5
20. 54 ATH+BSO N (–) (1+) 6.3 8
21. 44 ATH+BSO+PLN CYVADIC (1+) (1+) 30.3 11
22. 45 ATH+BSO CYVADIC (1+) (–) 9.7 7
23. 53 ATH+BSO CYVADIC (1+) (1+) 29.2 10
Table 2. Characteristics of patients with uterine leiomyoma
(mu): multiple myomas.
Case Age
Expression MIB-1 
Index
Tumor size 
maximum 
(cm) GLUT-1 HK II
1. 56 (–) (1+) 0.0 8 (mu)
2. 39 (–) (–) 0.0 8 (mu)
3. 49 (–) (–) 0.0 6 (mu)
4. 38 (–) (–) 0.0 14 (mu)
5. 46 (–) (–) 0.0 3 (mu)
6. 47 (1+) (1+) 0.0 14 (mu)
7. 73 (–) (–) 0.0 4 (mu)
8. 36 (–) (–) 0.0 25 (mu)
9. 69 (–) (1+) 0.0 5
10. 66 (–) (–) 0.0 4 (mu)
11. 27 (–) (–) 0.0 10 (mu)
12. 61 (1+) (–) 0.0 15 (mu)
13. 44 (–) (1+) 0.0 3 (mu)
14. 48 (–) (–) 0.0 6 (mu)
15. 52 (–) (–) 0.0 6
16. 50 (–) (–) 0.0 11 (mu)
17. 47 (–) (–) 0.0 25 (mu)
18. 46 (–) (–) 0.0 8 (mu)
19. 46 (–) (–) 0.0 8 (mu)
20. 47 (–) (–) 0.0 17
Fig. 4. Simple regression analysis of GLUT-1 expression and the
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patients given adjuvant chemotherapy of 8 cycles of doxo-
rubicin after resection and 61% in those who underwent
observation only, with no significant difference between the
groups [27]. A more recent randomized phase III trial of
adjuvant pelvic radiotherapy versus observation for stage I
and II uterine sarcomas (carcinosarcoma, leiomyosarcoma
or endometrial stromal sarcoma) indicated that radiotherapy
did not contribute to control of local metastasis or survival
rate [32]. Hensley et al. conducted a prospective study in
23 cases (stage I: 15, II: 3, III: 1, and IV: 4) of high grade
uterine LMS for a mean period of 49 months after complete
resection, and found that progression free survival (PFS)
at 2 years was 45% after treatment with gemcitabine 900
mg/m2 (on days 1 and 8 i.v.) plus docetaxel 75 mg/m2 (on
day 8 i.v.) for 4 cycles at 3-week intervals. The PFS in
stage I and II cases at 2–3 years was 59%, which suggested
that adjuvant chemotherapy with gemcitabine plus docetaxel
after complete resection may improve the prognosis of
early stage LMS [13]. Several pilot studies of adjuvant
therapies, including CYVADIC (cyclophosphamide, vin-
cristine, doxorubicin, and dacarbazine) therapy, ifosfamide
single therapy, and API (doxorubicin, cisplatin and ifosfa-
mide) plus radiotherapy have been conducted for early stage
LMS [21, 26, 30], with 3- and 5-year survival rates ranging
from 67% to 89% (one study with CYVADIC therapy had
a 15-year survival rate of 69%).
There is currently no established surgical procedure
or anticancer treatment for uterine sarcoma. This may be
because of the relatively small number of cases of uterine
sarcoma and because the disease is often not diagnosed
before surgery. Cases 1 and 2 were young patients who
underwent myomectomy and were diagnosed with uterine
sarcoma in a postoperative pathologic examination. Con-
sequently, these patients underwent hysterectomy in an
Fig. 5. Simple regression analysis of HK-II expression and the
MIB-1 index.
Fig. 6. Survival curves for GLUT-1-positive and GLUT-1-
negative cases of LMS.
Fig. 7. Survival curves of HK-II-positive and HK-II-
negative cases of LMS.Tsukada et al. 152
abdominal reoperation. Several small-scale studies have
indicated that CYVADIC chemotherapy improves prognosis
after total hysterectomy and adnexectomy [12, 31, 41]. In
our study, no gross residual tumor was found during lymph
node dissection. Twelve patients (52%) were treated with
CYVADIC chemotherapy and 9 (39%) did not receive this
chemotherapy. Three patients died in each of these groups.
Most previous studies and the current study were performed
at single centers and with a limited number of patients.
Therefore,  multicenter  randomized clinical trials are re-
quired to establish more reliable evidence of the efficacy
of treatment.
In our previous investigation of different histological
types (serous, mucous, endometrioid and clear cell) of
epithelial ovarian cancer, we found that expression levels
of GLUT-1 and HIF1α were correlated in the respective
histological types. Expression of both proteins was espe-
cially high in serous adenocarcinoma, which is frequently
found in epithelial ovary cancer, and clear cell adenocarci-
noma, which is chemoresistant and associated with recur-
rence and metastasis. Histopathologically, these two tumors
have fewer vascular vessels, but have papillary proliferation
and a stratified structure, and cause extensive necrosis in
progression. Therefore, hypoxia is induced as the cancer
progresses, and this leads to strong expression of GLUT-1
and HIF-1α [16, 43].
Many studies have evaluated the relationship between
the expression level of GLUT-1 and progression of epithelial
and gynecologic cancers, with the general finding that strong
GLUT-1 expression is associated with a poorer prognosis
[1, 6, 11, 17, 19, 44, 45]. In a study of 67 patients with bone
and soft tissue sarcoma or non-epithelial carcinoma (stage
IA–IVB, 15 different histological types), Endo et al. found
a correlation of prognosis with therapy including surgical
resection and adjuvant chemotherapy (p<0.0001), tumor
differentiation (p=0.017), necrotic grade (p=0.04), mitotic
grade (p=0.0198), MIB-1 grade (p=0.031), and GLUT-1
expression (p=0.029) in univariate analysis of 3-year
survival; but found that metastasis (p=0.031) was the only
significant prognostic factor in multivariate analysis of
overall survival. However, Kaplan-Meier estimates of
overall survival at 5 years were <40% in the GLUT-1-
positive group and 90% in the GLUT-1-negative group,
showing a significant difference in prognosis [8].
In the present study, all the cases of non-epithelial
carcinoma were in clinical stage I, involved uterine LMS
with a single histological type, and were completely
resectable in surgery. Thus, there was less variation in the
subjects in this study in comparison with Endo et al., which
included cases of different histological types and progres-
sion. The 5-year OS of all LMS patients was approximately
74%, and the MIB-1 index and expression level of GLUT-
1 had a significant positive correlation. The 5-year survival
rates were 90.9% and 58.3% in GLUT-1-negative and
GLUT-1-positive cases, respectively. Thus, GLUT-1 expres-
sion was significantly correlated with prognosis in uterine
LSM, as found in previous studies of malignant epithelial
tumors. In contrast, there was no relationship of HK-II
expression with the MIB-1 index or prognosis, and no
significant difference in survival between HK-II-positive
and HK-II-negative cases.
Previous studies have shown that expression of GLUT-
1 and HK-II in epithelial cancer cells, including breast,
esophageal, and lung cancer cells, plays a pivotal role in
glucose metabolism and that the expression levels of GLUT-
1 and HK-II are correlated with malignancy [5, 14, 17, 23,
28, 38]. The subjects of the current study were 23 patients
with LMS associated with non-epithelial malignancy and
the prognosis correlated with the presence or absence of
expression of GLUT-1 in malignant cells, but not with
expression of HK-II. Therefore, it is possible that the
occurrence of malignant cells depends on glucose metabo-
lism, glucose enzyme activity and phosphorylation, but not
on epithelial cell malignancy.
The recent development of [18F]-fluorodeoxyglucose
positron emission tomography (FDG-PET) allows imaging
based on the difference in glucose metabolism between
malignant and normal cells. Thus, FDG-PET is effective for
detection of early stage malignant tumors, and has high
sensitivity for detection of recurrence and metastasis in
malignant gynecological epithelial tumors [3, 4, 20, 35]. In
the first study of non-epithelial bone and soft tissue sarco-
mas using FDG-PET, Tateishi et al. showed an association
between higher GLUT-1 expression and a higher standard-
ized uptake value (SUV) of [18F]fluorodeoxyglucose,
thereby suggesting the efficacy of FDG-PET diagnostic
imaging for non-epithelial tumors, as well as MIB-1 grade,
mitotic grade, and tumor differentiation [36].
We have also evaluated FDG-PET for early detection
of recurrence and metastasis of advanced ovary cancer
after treatment. The rates of detection of intraperitoneal and
retroperitoneal metastasis by FDG-PET were 93.9% and
92.9%, respectively, and metastasis was detected in 14 (50%)
of 28 metastatic lymph nodes of normal size. FDG-PET
detected recurrence in 87.5% of CA125-positive patients
with no symptoms and negative results in conventional CT
and ultrasonography [24]. The efficacy of follow-up FDG-
PET was evaluated in patients with uterine LMS, and early-
stage minimal recurrent lesions were detected in patients in
whom conventional CT and ultrasonography did not show
intraperitoneal recurrence. Two of 5 patients underwent
reoperation for a recurrent tumor and survived for one year
or more after surgery.
Benign non-epithelial tumors such as uterine leiomyo-
mas are rarely positive in PET, but such cases should be
followed up carefully because some may be false-positives
[39]. However, FDG-PET is effective for detection of
early-stage intraperitoneal recurrence that may be over-
looked in conventional diagnostic imaging [25]. The
clinicopathological results reported here show that malig-
nant non-epithelial tumors have high glucose metabolic
activity and high GLUT-1 expression, and these findings
support the use of FDG-PET for detection of malignant
lesions.Long Term Prognosis Expression Glucose Transporter-1 and Hexokinase II Stage I Uterine Leiomyosarcoma 153
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